Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders

Clinical and Applied Immunology Reviews

Volumn 2, Issue 4-5, 2002, Pages 241-253

  Richards, Susan M ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Antibody; Enzyme replacement therapy; Immune response; Lysosomal storage disease; Therapeutic protein

Indexed keywords

ALPHA GALACTOSIDASE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSYLCERAMIDASE; LEVO IDURONIDASE; LYSOSOME ENZYME; MANNOSE 6 PHOSPHATE; RECOMBINANT ENZYME; SPHINGOMYELIN PHOSPHODIESTERASE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; CELL FUNCTION; CLINICAL STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME METABOLISM; ENZYME REPLACEMENT; ENZYME SUBSTRATE; ENZYME SYNTHESIS; FABRY DISEASE; GAUCHER DISEASE; GENE MUTATION; GENETIC DISORDER; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HURLER SYNDROME; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LYSOSOME; LYSOSOME STORAGE DISEASE; MONITORING; MORTALITY; NIEMANN PICK DISEASE; PATIENT CARE; RADIOIMMUNOASSAY; REVIEW; SYMPTOM;

EID: 0036663391     PISSN: 15291049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1529-1049(02)00049-1     Document Type: Review

References (44)

1. Hopwood JJ, Brooks DA. An introduction to the basic science and biology of the lysosome and storage disease. In: Applegarth D, Dimmick J, Hall J, editors. Organelle diseases. London: Chapman Hall; 1997. p. 7-35.
2. Meikle PJ, Hopwood JJ, Claque AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281:249-54.
3. Furbish FS, Steer CJ, Barranger JA, Jones EA, Brady RO. The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and kupffer cells. Biochem Biophys Res Commun 1978;81:1047-53.
4. Barton NW, Bradley RO, Dambrosia JM, DiBiseglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited deficiency macrophage targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324:1464-70.
5. Meikle PJ, Ramieri E, Ravenscroft EM, Hua CT, Brooks DA, Hopwood JJ. Newborn screening for lysosomal storage disorders. Southeast Asian J Trop Med Public Health 1999;30:104-10.
6. National Institute of Health Technology Assessement Conference Statement. Gaucher disease: current issues in diagnosis and treatment. Bethesda: NIH, 1995.
7. Beutler E, Grawbowski GA. Gaucher disease. In: Scriver C, Beaudet A, Valle D, Sly W, editors. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 3635-68.
8. Desnick RJ, Ioannou YA, Eng CM.α-Galactosidase A deficiency: Fabry disease. In: Beaudet A, Valle D, Scriver C, Sly W, editors. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 3733-74.
9. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
10. Schiffmann R, Kopp JB, Austin III HA, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease. JAMA 2001;285:2743-9.
11. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver C, Beaudet A, Valle D, Sly W, editors. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 3421-52.
12. Kakkis ED, Muenzer J. Enzyme replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-8.
13. Hirschhorn R, Reuser AJ. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. In: Scriver C, Beaudet A, Valle D, Sly W, editors. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 3389-20.
14. Van den Hout H, Reuser AJJ, Vulto AG, Loonen MCB, Dijkhuis AC, Van der Ploeg AT. Recombinant human α-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356:397-8.
15. Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, et al. Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3:132-8.
16. Van den Hout H, Reuser AJJ, deKlerk JBC, Arts WF, Smeitink JAM, Van der Ploeg AT. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 2001;24:266-74.
17. Kishnani P, Voit T, Nicolino M, Amalfitano A, Straub V, Klinge L, et al. Safety and efficacy of recombinant human acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: preliminary 3 month data from a Phase 2 study. Genetics in Medicine 2002; May/June (Abstract from American College of Medical Genetics Meeting 2002) (in press).
18. Porter S. Human immune response to recombinant human proteins. J Pharm Sci 2001;90:1-11.
19. Richards SM, Olson TA, McPherson JM. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocrebrosidase. Blood 1993;82:1402-9.
20. Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM. Immunosurveillance of Alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999;93:2081-8.
21. Kingma W, Rosenberg M, Richards SM. Antibody formation in patients receiving Imiglucerase and impact on safety and clinical response. Gaucher Clinical Perspectives 1998;6:8-11.
22. Pastores GM, Sibille AR, Grabowski G. Enzyme therapy in Gaucher disease type I: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 1993;82:408-16.
23. Ponce E, Moskovitz J, Grabowski G. Enzyme therapy in Gaucher disease type I: effect of neutralizing antibodies to acid α-glucosidase. Blood 1997;90:43-8.
24. Brady RO, Murray GJ, Oliver KL, Leitman SF, Sneller MC, Fleisher TA, et al. Management of neutralizing antibodies to ceredase in a patient with type 3 Gaucher disease. Pediatrics 1997;100:111-4.
25. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, et aql. A multicenter study of recombinant factor VIII: safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994;83:2428-35.
26. White GC, Greenwood R, Escobar M, Frelinger JA. Hemophilia factor VIII therapy, immunological tolerance. A clinical perspective. Haematologica 2000;85:113-6.
27. Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S. Immunogenicity of recombinant DNA human insulin. Diabetologia 1983;25:465-9.
28. Marshall MO, Heding LG, Villumsen J, Akerblom HK, Baevre H, Dahlquist G, et al. Development of insulin antibodies, metabolic control and B-cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin. Diabetes Res 1988;9:169-75.
29. Kaplan SL, August GP, Blethen SL. Clinical studies with recombinant-DNA-derived methionyl human growth hormone deficient children. Lancet 1986;1(8483):697-700.
30. Rouget C, Marchand P, Dray F, Girard F, Job JC, Pierson M, et al. Comparative study of biosynthetic human growth hormone immunogenicity in growth hormone deficient children. Horm Res 1991;35:76-81.
31. Kahn CR, Rosenthal AS. Immunologic reactions to insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care 1979;2:283-95.
32. Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 1980;5:691-7.
33. McEvoy RC, Witt ME, Ginsberg-Fellner F, Rubinstein G. Anti-insulin antibodies in children with type I diabetes mellitus. Diabetes 1986;35:634-41.
34. Brooks DA. Review: immunochemical analysis of lysosomal enzymes in mucopolysaccharidosis type I and type VI patients. J Inherit Metab Dis 1998;16:3-15.
35. Lawler GL, Fischer TJ. eds. Manual of allergy and immunology. Boston: Little, Brown and Company, 1995.
36. Janeway CA, Travers P, Walport M, Shlomchik M. Immunobiology: the immune system in health and disease. 5th ed. New York: Garland Publishing, 2001.
37. Turner CT, Hopwood JJ, Brooks DA. Enzyme replacement therapy in Mucopolysaccharidosis I: altered distribution and targeting of α-L- Iduronidase in immunized rats. Mol Gen Metab 2000;69:277-85.
38. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors. Blood 2000;95(5):1698-702.
39. Ho AY, Height SE, Smith MP. Immune tolerance therapy for haemophilia. Drugs 2000;60:547-54.
40. Lusher JM. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials. Haematologica 2000;85:2-6.
41. McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG. Clinical status and optimal use of rituximab for β-cell lymphomas. Oncology 1998;12:1763-9.
42. Grillo-Lopez AJ. Rituximab: an insider's historical perspective. Semin Oncol 2000;27:9-16.
43. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000;27:79-85.
44. Steis RG, Smith II JW, Urba WJ, Venzon DJ, Longo DL, Barney R, et al. Loss of interferon antibodies during prolonged continuous interferon-α2a therapy in hairy cell leukemia. Blood 1991;77:792-8.